Market behaved this morning as if missing the OS primary endpoint was news. Big attempt to push the SP down in response, but it quickly bounced back. You would think that the buy back starting should improve matters.
Was glad to see that the OS benefit in right sided tumours was highlighted in the subgroup analysis and made it to a key bullet point in the conclusion slide. It's a clear message to watch this space.
WCGIC is only a couple of weeks away and I expect to see some impressive survival curves, hopefully with some extra data from FOXFIRE. Will be very interested to get some feedback from Sirtex regarding what steps are needed to translate this finding into sales. Confirmation that 1st line sales will proceed for this subgroup should see a significant re-rate.
SRX Price at posting:
$11.54 Sentiment: Buy Disclosure: Held
